89/100 A · Low risk
No major risk flags in the public sources we cover Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.

ℹ️ No matches surfaced in the limited public sources we cover (sanctions, screening, insolvency, control). This is an automated indicator — not an exhaustive check, a credit decision, or a guarantee, and absence of a match does not mean none exists. Verify against the official register.

Think this is wrong? This is an automated estimate — request a human review or correction.

GALDERMA RESEARCH & DEVELOPMENT

Active General partnership (SNC) Scientific research & development Active for 47 years

General partnership (SNC) · RC 317099679 · Active since 1979

A

Overview

GALDERMA RESEARCH & DEVELOPMENT is a general partnership (snc) registered in France, since 1979. The company operates in the scientific research & development sector. Its TraceComp score of 89 (A) indicates solid fundamentals and low apparent risk. With 47 years of operations, the company has an established track record in its market.

Company Information

Registration Number
317099679
Legal Form
General partnership (SNC)
Registered
1979-01-01

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) —
Net Income 9,405,897 EUR
Total Assets 43,930,171 EUR
Altman Z 4.82 safe

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Patent Portfolio

Active patent holder. 251 patents · 201 active · 251 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Profitable: positive net income in FY 2024
  • Altman Z-Score in the safe zone

Data Sources & Freshness

Data sourced from: bulk register.